<DOC>
	<DOCNO>NCT01087983</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose 2 different combination drug give patient advanced cancer . The first combination drug Tykerb ( lapatinib ) Rapamune ( sirolimus ) , second combination lapatinib Glucophage ( metformin ) . The safety drug combination also study .</brief_summary>
	<brief_title>Lapatinib With Sirolimus Metformin</brief_title>
	<detailed_description>The Study Drugs : Lapatinib design prevent slow growth cancer cell block 2 protein surface cancer cell , HER 1 HER 2 receptor . Sirolimus design block protein call mammalian target rapamycin ( mTOR ) ( protein think cause cancer cell grow ) inside cancer cell . This may interfere growth spread cancer cell possibly kill cancer cell . Metformin design treat patient diabetes . It may able block mTOR slow growth tumor . Study Drug Groups : If find eligible take part study , doctor decide receive lapatinib metformin lapatinib sirolimus . Once decided combination receive , assign dose level base join study . Up 7 dose level lapatinib sirolimus test . Up 6 dose level lapatinib metformin test . Three ( 3 ) 6 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose combination lapatinib either sirolimus metformin find . Once high tolerate dose combination lapatinib either sirolimus metformin find , 14 participant tumor type respond study drug combination receive study drug dose level . Study Drug Administration : Each study `` cycle '' 28 day . You take lapatinib mouth 1 time day . You take time day empty stomach cup ( 8 ounce ) water , 1 hour 2 hour meal . If also take metformin , take mouth 1 time every day . You take time day meal cup water ( 8 ounce ) . If also take sirolimus , take mouth 1 time every day . You take time day empty stomach cup water , 1 hour 2 hour meal . Study Visits : At every study visit , ask current health condition , drug take , experienced side effect . On Days 1 , 8 , 15 Cycle 1 , blood ( 2 teaspoon ) draw routine test . On Day 1 Cycle 1 , urine collect routine test . On Day 1 Cycles 2 beyond : - You physical exam . - Blood ( 2 teaspoon ) urine collect routine test . Every 6 week , blood ( 1 teaspoon ) drawn urine collect pregnancy test able become pregnant . Every 8 week first 4 cycle , x-ray , CT scan , MRI scan , and/or PET/CT scan check status disease . If study doctor think need , perform often . After 4 cycle x-ray , CT scan , MRI scan , and/or PET/CT scan every 8 - 12 week study study doctor feel appropriate . Length Study : You may stay study long benefitting . You take study experience intolerable side effect , study doctor think best interest , disease get bad . This investigational study . Sirolimus FDA approve commercially available anti-rejection drug kidney transplant recipient . Lapatinib FDA approve commercially available treatment advance breast cancer . Metformin FDA approve commercially available treatment diabetes mellitus . The combination drug treat advance cancer investigational . Up 106 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>1 . Patients advance metastatic cancer refractory standard therapy , relapse standard therapy , standard therapy available improves survival least three month . 2 . Patients must least 3 week beyond previous cytotoxic treatment . Patient must wait least 5 halflives 3 week , whichever short , previous target biologic therapy ; In addition , patient must least 3 week beyond last session radiation therapy major surgery . Local palliative radiation therapy deliver target lesion allow immediately treatment . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 3 4 . Patients must normal organ marrow function define : absolute neutrophil count ( ANC ) &gt; /= 750/mL ; platelet &gt; /= 50,000/mL ; creatinine &lt; /= 2x upper limit normal ( ULN ) Sirolimus Arm creatinine &lt; 1.5 mg/dl Metformin arm ; total bilirubin &lt; /=2.0 ( For patient Gilbert syndrome , bilirubin level &gt; 2 could allow study hyperbilirubinemia believe secondary Gilbert syndrome ) ; ALT ( SGPT ) &lt; /= 5x ULN ; Exception patient liver metastasis : total bilirubin &lt; /= 3x ULN ; ALT ( SGPT ) &lt; /= 8x ULN . 5 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 30 day last dose 6 . Patients must able understand willing sign write informed consent document 7 . Patients treat brain metastasis allow arm study . 1 . Uncontrolled intercurrent illness include , limited , uncontrolled infection , uncontrolled asthma , need hemodialysis , need ventilatory support . 2 . Pregnant lactating woman . 3 . History hypersensitivity Lapatinib component formulation . 4 . Patients malabsorption syndrome 5 . Patients class III IV congestive heart failure define New York Heart Association functional classification system 6 . Patients unwilling unable sign inform consent document 7 . History hypersensitivity Sirolimus component formulation ( Lapatinib Sirolimus arm ) 8 . History hypersensitivity metformin component formulation ( Lapatinib Metformin arm )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Metastatic cancer</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>Tykerb</keyword>
	<keyword>Metformin</keyword>
	<keyword>Glucophage</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Rapamune</keyword>
</DOC>